Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
159.94B
Market cap159.94B
Price-Earnings ratio
40.72
Price-Earnings ratio40.72
Dividend yield
6.04%
Dividend yield6.04%
Average volume
36.98M
Average volume36.98M
High today
$28.54
High today$28.54
Low today
$28.00
Low today$28.00
Open price
$28.06
Open price$28.06
Volume
37.66M
Volume37.66M
52 Week high
$31.44
52 Week high$31.44
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $28.01. The company's market cap stands at 159.94B, with a P/E ratio of 40.72 and a dividend yield of 6.04%.

On 2026-11-18, Pfizer(PFE) stock moved within a range of $28.00 to $28.54. With shares now at $28.01, the stock is trading +0.0% above its intraday low and -1.8% below the session's peak.

Trading activity shows a volume of 37.66M, compared to an average daily volume of 36.98M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $31.44 and a low of $23.62.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $31.44 and a low of $23.62.

PFE News

TipRanks 12h
H.C. Wainwright positive on Legend Biotech after Pfizer CAR-T deal

H.C. Wainwright reiterates a Buy rating on Legend Biotech (LEGN) with a $65 price target after Pfizer (PFE) announced an agreement to license three in vivo CAR-...

Benzinga 13h
Pfizer Strikes Multibillion-Dollar Deal to Take on Autoimmune Diseases

Pfizer Inc. (NYSE:PFE) announced Wednesday an exclusive licensing agreement with Starna Therapeutics worth up to $2.63 billion in upfront and milestone payments...

Pfizer Strikes Multibillion-Dollar Deal to Take on Autoimmune Diseases
Seeking Alpha 16h
Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B

Pfizer (PFE) on Wednesday announced an exclusive licensing agreement with China-based RNA medicines company Starna Therapeutics to develop and commercialize chi...

Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B

Analyst ratings

63%

of 27 ratings
Buy
25.9%
Hold
63%
Sell
11.1%

More PFE News

TipRanks 17h
Pfizer enters exclusive licensing agreement with Starna Therapeutics

Pfizer (PFE) announced that it entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed...

Simply Wall St 1d
What Is Pfizer Asking Of Its $10 Billion Metsera Bet?

Pfizer (NYSE:PFE) agreed to acquire obesity drug developer Metsera for about US$10b in cash, expanding its metabolic disease portfolio. The deal strengthens Pf...

What Is Pfizer Asking Of Its $10 Billion Metsera Bet?
24/7 Wall St. 1d
Wall Street Forgot These 3 Dividend Stocks — Now They Pay Over 5%

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

Wall Street Forgot These 3 Dividend Stocks — Now They Pay Over 5%
The Motley Fool 1d
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue

Johnson & Johnson: Steady Upward Recent Revenue Growth Johnson & Johnson (JNJ -0.97%) primarily generates revenue by developing and selling pharmaceutical and m...

Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
TipRanks 2d
Pfizer Updates Real-World Safety Study of Xeljanz XR

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer’s study, officially titled “KOREAN POST-MARKETING SURVEILLANCE FOR...

Simply Wall St 3d
Is Pfizer Undervalued On Its $1.5b Berobenatide Funding Deal?

Pfizer (PFE) just secured up to US$1.5b in external funding from Blackstone Life Sciences for berobenatide, its investigational monthly GLP 1 obesity drug, whil...

Is Pfizer Undervalued On Its $1.5b Berobenatide Funding Deal?
The Motley Fool 4d
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

As the global health landscape shifts toward obesity treatments, investors are weighing the rapid growth of Novo Nordisk A/S (NVO +2.41%) against the deep-roote...

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.